AVX 101

Drug Profile

AVX 101

Alternative Names: Alphavirus replicon HIV-1 subtype C Gag vaccine (AVX101); AVX-101; Single gene HIV vaccine - AlphaVax

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaVax
  • Developer AlphaVax; National Institutes of Health (USA)
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 01 Oct 2012 Final immunogenicity and adverse events data from two phase I trials (HVTN 040 and HVTN 059) published in Clinical and Vaccine Immunology
  • 26 Oct 2010 NIAID discontinues a phase I trial in healthy adults in USA and South Africa (HVTN 040; NCT00063778)
  • 23 Sep 2009 AlphaVax discontinues a phase I trial in healthy adults in USA, South Africa and Botswana (HVTN 059; NCT00097838)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top